Vaccine manufacturing companies focus on creating vaccines to prevent diseases, contributing significantly to global health. This industry includes large players like Serum Institute and Bharat Biotech, as well as smaller firms innovating in niche markets. Companies are harnessing cutting-edge technology to enhance vaccine development and distribution. With the recent push for public health improvements, the demand for vaccines is likely to grow, prompting manufacturers to scale operations and invest in R&D. Strategic partnerships and collaborations are also on the rise, as industries unite to tackle emerging health threats and ensure equitable access to vaccines worldwide.


The featured companies represent a mix of sizes, from emerging firms like Mynvax Private Limited with fewer than 50 employees to established giants like Serum Institute with over 5,000. Headquartered in countries such as India, South Africa, and China, these companies were founded at various times, from 1953 to as recently as 2023. Each specializes in unique areas of vaccine development, including COVID-19 solutions and animal health vaccines, showcasing a global effort to meet pressing health challenges in an evolving landscape.


Continue reading to discover the top vaccine manufacturing companies.


Top 24 Vaccine Manufacturing Companies


1. Serum Institute of India Pvt. Ltd.


Serum Institute of India Pvt. Ltd., based in Pune, Maharashtra, is a prominent vaccine manufacturer that has been operational since 1966. The company focuses on the production of immuno-biologicals, offering a wide range of vaccines aimed at combating various infectious diseases. With a workforce of over 5,000 employees, Serum Institute is dedicated to advancing public health through its innovative vaccine solutions. The company has made significant strides in research and development, continually working to improve the efficacy and safety of its products. Notably, Serum Institute has been instrumental in the global response to the COVID-19 pandemic by producing COVISHIELD, a widely used vaccine developed in collaboration with AstraZeneca. Their commitment to quality and accessibility has positioned them as a key supplier for healthcare providers and public health organizations worldwide.


2. Bharat Biotech

  • Website: bharatbiotech.com
  • Ownership type: Venture Capital
  • Headquarters: Hyderabad, Telangana, India
  • Employee distribution: India 99%
  • Latest funding: Other (Grant), $14.1M, June 2020
  • Founded year: 1996
  • Headcount: 1001-5000
  • LinkedIn: bharat-biotechil

Bharat Biotech International Limited, based in Hyderabad, Telangana, India, is a biotechnology company that specializes in the development and manufacturing of vaccines and biotherapeutics. Established in 1996 by Dr. Krishna M. Ella and Mrs. Suchitra Ella, the company has focused on creating innovative solutions to combat infectious diseases, particularly in underserved regions. Bharat Biotech has developed a wide array of vaccines, including Biohib, Biopolio, and the COVID-19 vaccine COVAXIN, which has gained international recognition. The company is committed to research and development, with a significant investment in creating effective vaccines for diseases like Chikungunya and Zika. Bharat Biotech's manufacturing facilities are approved by major health authorities, ensuring that their products meet global safety and quality standards. The company has also received funding, including a grant of $14.1 million in 2020, to support its initiatives in vaccine development. With a workforce of over 1,800 employees, Bharat Biotech continues to strive for advancements in public health through its innovative products and research efforts.


3. Biological E. Limited

  • Website: biologicale.com
  • Ownership type: Venture Capital
  • Headquarters: Hyderabad, Telangana, India
  • Employee distribution: India 100%
  • Latest funding: $50.0M, October 2021
  • Founded year: 1953
  • Headcount: 1001-5000
  • LinkedIn: biological-e--ltd

Biological E. Limited, based in Hyderabad, Telangana, India, is a biotechnology and biopharmaceutical company established in 1953. The company specializes in the production of vaccines and biologics, with a strong emphasis on providing affordable healthcare solutions. Over the years, Biological E. has transitioned from manufacturing liver extracts and anti-coagulants to focusing on vaccines, launching its Biotechnology Division in the 1960s. Today, it operates three main business units: Branded Formulations, Specialty Generic Injectables, and Vaccines & Biologics. The company has made significant strides in vaccine development, including the recent approval of CORBEVAX, India's first indigenously developed protein sub-unit COVID-19 vaccine. Biological E. Limited is committed to quality and safety in its products, supported by a robust quality management system. The company has also received funding, with a notable amount reported in 2021, indicating ongoing investment in its operations and growth.


4. Biovac

  • Website: biovac.co.za
  • Ownership type: Corporate
  • Headquarters: Cape Town, Western Cape, South Africa
  • Employee distribution: South Africa 99%
  • Latest funding: June 2016
  • Founded year: 2003
  • Headcount: 201-500
  • LinkedIn: the-biovac-institute

Biovac is a biopharmaceutical company based in Cape Town, South Africa, founded in 2003. The company focuses on the development and manufacturing of vaccines, playing a crucial role in supplying vaccines for the Expanded Programme on Immunisation in South Africa. With a workforce of approximately 472 employees, Biovac is dedicated to enhancing local vaccine production capabilities to meet the healthcare needs of the region. They have invested significantly in infrastructure and skills development, establishing a state-of-the-art manufacturing facility that adheres to current Good Manufacturing Practices (cGMP). Biovac has developed a technology package for the manufacture of the Haemophilus influenzae type b (Hib) conjugate vaccine, which has been successfully transferred to international partners. Their commitment to collaboration is evident through partnerships with organizations like the University of Cape Town and Sanofi Pasteur, aimed at building capacity in vaccine development and manufacturing. Biovac's efforts contribute to addressing the critical shortage of vaccine manufacturing in Africa, where the continent relies heavily on imported vaccines.


5. Indian Immunologicals Limited


Indian Immunologicals Limited (IIL), founded in 1982 and based in Hyderabad, Telangana, is a private healthcare company focused on the development and manufacturing of vaccines for both animals and humans. With a workforce of approximately 1,785 employees, IIL operates one of the largest plants for veterinary vaccines globally. The company has a robust portfolio of over 150 registered products, including vaccines that cater to public health needs, particularly in pediatric and rabies vaccine segments. IIL has been instrumental in supplying vaccines to government ministries and healthcare institutions, ensuring the health and safety of populations. Their commitment to research and development has led to collaborations with various national and international institutes, enhancing their product offerings. IIL exports its vaccines to more than 50 countries, showcasing its global reach and impact in the vaccine manufacturing industry.


6. SINERGIUM Biotech

  • Website: sinergiumbiotech.com
  • Ownership type: Private
  • Headquarters: Garin, Buenos Aires, Argentina
  • Employee distribution: Argentina 100%
  • Founded year: 2011
  • Headcount: 201-500
  • LinkedIn: sinergium-biotech

SINERGIUM Biotech is a private biopharmaceutical company located in Garin, Buenos Aires, Argentina. Established in 2011, the company specializes in the research, development, production, and commercialization of vaccines and complex biopharmaceutical products. With a workforce of approximately 267 employees, SINERGIUM operates a state-of-the-art manufacturing facility that adheres to international Good Manufacturing Practices (GMP). The company is dedicated to improving public health by providing high-quality medical solutions to healthcare providers and government health agencies. SINERGIUM has formed strategic alliances with both national and international laboratories, allowing for the transfer of cutting-edge technologies and the production of vaccines that were previously imported. Notably, SINERGIUM was selected by the World Health Organization (WHO) in 2021 to receive technology transfer for mRNA vaccine production, further solidifying its role in the global vaccine supply chain. The company aims to enhance local production capabilities and reduce dependency on external sources, thereby contributing to regional health security.


7. AJ Vaccines

  • Website: ajvaccines.com
  • Ownership type: Private
  • Headquarters: Frederiksberg, Frederiksberg, Denmark
  • Employee distribution: Denmark 100%
  • Founded year: 2017
  • Headcount: 501-1000
  • LinkedIn: aj-vaccines

AJ Vaccines A/S, based in Frederiksberg, Denmark, is a healthcare solutions provider that specializes in the development and manufacturing of vaccines, diagnostics, and therapeutic solutions. Established in 2017 following the divestment of vaccine production from Statens Serum Institut, AJ Vaccines has a rich history rooted in over a century of vaccine development in Denmark. The company is dedicated to enhancing public health and disease control, contributing to vaccination programs in more than 50 countries. Their product offerings include vaccines for various infectious diseases, as well as diagnostic tools, primarily aimed at healthcare organizations and public health entities. AJ Vaccines is also involved in the production of Tuberculin Skin Tests and BCG Culture for bladder cancer treatment, showcasing their commitment to addressing both infectious diseases and cancer care.


8. Vabiotech

  • Website: vabiotech.com.vn
  • Ownership type: Private
  • Headquarters: Trung Hoà, Hanoi, Vietnam
  • Founded year: 2000
  • Headcount: 1-10
  • LinkedIn: vabiotech

Vabiotech, officially known as Công ty TNHH MTV Vắc xin và Sinh phẩm số 1, is a biotechnology firm based in Hanoi, Vietnam. Established in 2000, Vabiotech specializes in the production of vaccines and biological products aimed at preventing diseases. The company serves healthcare providers and government health departments, ensuring a steady supply of high-quality vaccines. Vabiotech manufactures several vaccines, including HAVAX® for Hepatitis A, Gene-HBvax for Hepatitis B, JEVAX® for Japanese Encephalitis, and mORCVAX for oral Cholera. In addition to its production capabilities, Vabiotech is actively involved in research and development, focusing on innovative vaccine technologies. The company adheres to strict quality standards, operating under WHO-GMP and ISO 9001:2015 certifications, which underscores its commitment to quality and safety in vaccine manufacturing.


9. Walvax

  • Website: en.walvax.com
  • Ownership type: Private
  • Headquarters: Kunming, Yunnan, China
  • Employee distribution: China 95%, Philippines 5%
  • Founded year: 2001
  • Headcount: 1001-5000
  • LinkedIn: walvax-biotechnology-co-ltd

Walvax Biotechnology Co., Ltd., based in Kunming, Yunnan, China, is a prominent player in the vaccine manufacturing sector. Founded in 2001, the company specializes in the research, development, and distribution of vaccines aimed at combating infectious diseases. With a portfolio that includes eight licensed vaccines, such as the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) and the Recombinant Human Papillomavirus Bivalent Vaccine (HPV2), Walvax has made significant strides in public health. The company operates four manufacturing centers across China, with a notable focus on mRNA vaccine production. Their commitment to innovation is reflected in their substantial investment in R&D, which exceeds 20% of their revenue. Walvax has successfully delivered over 228 million doses to the Chinese market and has expanded its reach to 20 countries worldwide. The company is also actively pursuing WHO prequalification for several of its products, aiming to enhance its international market presence. Through collaborations with organizations like the Bill & Melinda Gates Foundation, Walvax is positioned to contribute meaningfully to global health initiatives.


10. FORT Biopharmaceutical company


FORT Biopharmaceutical company, based in Moscow, Russia, is a private biopharmaceutical firm established in 2006. The company specializes in the production of vaccines designed to prevent infectious diseases, catering to healthcare professionals and distributors. FORT is dedicated to ensuring public health through effective vaccination solutions, adhering to stringent regulatory standards. The company operates a full-cycle production facility that meets international Good Manufacturing Practice (GMP) standards. FORT's flagship vaccine, 'Ультрикс Квадри', has demonstrated significant efficacy and is approved for use across various age groups. The company has also engaged in initiatives to increase vaccination awareness and has participated in health forums, showcasing its commitment to the industry. With a workforce of 201-500 employees, FORT is positioned as a significant player in the Russian biopharmaceutical landscape, focusing on innovative solutions to combat infectious diseases.


11. Hipra

  • Website: hipra.com
  • Ownership type: Private
  • Headquarters: Amer, Catalonia, Spain
  • Employee distribution: Spain 50%, Brazil 8%, India 7%, Other 35%
  • Founded year: 1954
  • Headcount: 1001-5000
  • LinkedIn: hipra

Hipra, founded in 1954 and headquartered in Amer, Catalonia, Spain, is a private biotechnology company with a workforce of approximately 1,845 employees. The company specializes in the research, production, and commercialization of vaccines aimed at both animal and human health. Hipra has made significant strides in developing innovative vaccines, including a COVID-19 vaccine, showcasing their ability to respond to urgent health needs. Their product offerings also extend to digestive health solutions. With a strong international presence, Hipra operates in over 40 countries and has multiple research centers and production plants strategically located in Europe and America. Their commitment to health and innovation is evident in their ongoing research and development projects, which aim to enhance disease prevention across various therapeutic areas.


12. Zendal

  • Website: zendal.com
  • Ownership type: Private
  • Headquarters: Torneiros, Ourense, Spain
  • Employee distribution: Spain 78%, Portugal 22%
  • Founded year: 1993
  • Headcount: 501-1000
  • LinkedIn: zendal

Zendal is a private biopharmaceutical company based in Torneiros, Ourense, Spain, founded in 1993. The company focuses on the research, development, and manufacturing of vaccines and biological products aimed at improving health outcomes for both humans and animals. With a workforce of around 650 employees, Zendal operates through several subsidiaries, including CZ Vaccines and Biofabri, which are dedicated to vaccine development and production. The company has been involved in significant projects, such as the development of vaccines for COVID-19 and tuberculosis, showcasing its commitment to addressing global health challenges. Zendal serves a variety of clients, including governments and multinational corporations, providing innovative health solutions. Their extensive experience and ongoing projects in vaccine development underscore their relevance in the biopharmaceutical industry.


13. CZ Vaccines

  • Website: czvaccines.com
  • Ownership type: Corporate
  • Headquarters: Sabaceda, Pontevedra, Spain
  • Employee distribution: Spain 99%, Other 1%
  • Latest funding: $167.0M, May 2020
  • Founded year: 1993
  • Headcount: 201-500
  • LinkedIn: cz-vaccines

CZ Vaccines, based in Sabaceda, Pontevedra, Spain, is a biotechnology firm founded in 1993. The company specializes in the development and manufacturing of vaccines and biological products aimed at both human and animal health. They offer contract development and manufacturing organization (CDMO) services to multinational companies and governments, focusing on innovative solutions to combat viral and bacterial diseases. With a strong emphasis on research and development, CZ Vaccines has capabilities in various vaccine platforms, including conventional vaccines, live attenuated vaccines, recombinant protein subunit vaccines, and cutting-edge DNA vaccines. Their facilities are equipped for large-scale production, adhering to stringent quality control standards. In 2020, CZ Vaccines secured significant funding of €167 million, which underscores their commitment to advancing vaccine technology and expanding their operational capacity.


14. MSD Sharp & Dohme GmbH

  • Website: msd.de
  • Ownership type: Private
  • Headquarters: Amt Neuhaus, Lower Saxony, Germany
  • Founded year: 2001
  • Headcount: 1001-5000
  • LinkedIn: msd-sharp-%26-dohme-gmbh

MSD Sharp & Dohme GmbH, a subsidiary of Merck & Co., Inc., is a pharmaceutical company based in Amt Neuhaus, Lower Saxony, Germany. Founded in 2001, the company specializes in the research, development, and manufacturing of medications and vaccines. MSD is dedicated to providing innovative healthcare solutions, particularly in oncology and infectious diseases. Their vaccine portfolio includes efforts to combat serious health threats, such as the Ebola virus, showcasing their commitment to global health. MSD operates with a workforce of approximately 2,438 employees and is recognized as one of the prominent pharmaceutical manufacturers in Germany. The company emphasizes accessibility to healthcare solutions, aiming to improve health outcomes worldwide through their products and initiatives.


15. NPO Petrovax Pharm LLC

  • Website: petrovax.ru
  • Ownership type: Venture Capital
  • Headquarters: Moscow, Moscow, Russia
  • Latest funding: February 2014
  • Founded year: 1996
  • Headcount: 501-1000
  • LinkedIn: npo-petrovax-pharm-llc

NPO Petrovax Pharm LLC, founded in 1996 and based in Moscow, Russia, is a biotechnology company that focuses on the development and manufacturing of original pharmaceuticals and vaccines. The company operates a full-cycle production facility that meets international standards, ensuring high-quality output. Petrovax is known for its innovative treatments targeting significant health issues, particularly in the realm of infectious diseases. Their product portfolio includes vaccines such as Grippol® plus and Grippol® Quadrivalent, as well as the pneumococcal vaccine Prevenar® 13. The company has established itself as a significant player in the Russian pharmaceutical market, emphasizing research and development to drive innovation. Petrovax also engages in international cooperation and exports, further solidifying its position in the global market. The company has a robust R&D center and has been involved in various clinical studies, including those related to COVID-19 treatments. With a workforce of around 500 to 1000 employees, Petrovax continues to expand its capabilities and product offerings.


16. Petrovax Pharm

  • Website: petrovax.com
  • Ownership type: Private Equity
  • Headquarters: Moscow, Moscow, Russia
  • Employee distribution: Russia 96%, Uzbekistan 2%, Kazakhstan 2%
  • Latest funding: October 2022
  • Founded year: 1996
  • Headcount: 501-1000
  • LinkedIn: npo-petrovax-pharm-llc

Petrovax Pharm, founded in 1996 and based in Moscow, Russia, is a biotechnology company that specializes in the development and manufacturing of original pharmaceutical products and vaccines. The company operates a full-cycle biotechnological manufacturing facility that complies with international standards, including EU GMP. Petrovax Pharm's product portfolio includes vaccines for influenza, such as Grippol® plus and Grippol® Quadrivalent, as well as the Prevenar® 13 vaccine. They are recognized as one of the largest exporters of original pharmaceutical products and vaccines in Russia. The company has a strong emphasis on research and development, with a focus on socially significant diseases, including oncological and infectious diseases. Petrovax Pharm collaborates with international partners, including Pfizer and Abbott, to enhance its production capabilities and expand its market reach. Their commitment to quality and innovation is evident in their extensive manufacturing capacity and ongoing clinical studies.


17. GSK Canada

  • Website: gsk.ca
  • Ownership type: Private
  • Headquarters: Mississauga, Ontario, Canada
  • Founded year: 1906
  • Headcount: 1001-5000
  • LinkedIn: gsk-canada

GSK Canada, based in Mississauga, Ontario, is a biopharmaceutical company that specializes in the development of innovative vaccines and specialty medicines. Founded in 1906, GSK has a long-standing commitment to improving health outcomes through advanced research and development. The company focuses on therapeutic areas such as infectious diseases and oncology, with a significant emphasis on vaccine production. GSK Canada has invested over $2 billion in pharmaceutical and vaccine research and development since 2001, highlighting their dedication to innovation in the healthcare sector. Their product offerings include a range of vaccines targeting various infectious diseases, demonstrating their active involvement in addressing public health challenges. GSK Canada operates a vaccine production facility in Ste-Foy, Quebec, which plays a crucial role in their manufacturing capabilities.


18. Intravacc

  • Website: intravacc.nl
  • Ownership type: Private
  • Headquarters: Bilthoven, Utrecht, Netherlands
  • Employee distribution: Netherlands 100%
  • Latest funding: Other (Grant), $633,000, January 2024
  • Founded year: 2013
  • Headcount: 51-200
  • LinkedIn: intravacc

Intravacc, founded in 2013 and based in Bilthoven, Utrecht, Netherlands, is a private vaccine development company that specializes in contract development and manufacturing organization (CDMO) services. With a workforce of approximately 64 employees, Intravacc is dedicated to advancing public health through innovative vaccine solutions. The company offers a comprehensive range of services, from vaccine development to GMP manufacturing, catering to biotech firms, governmental agencies, and NGOs. Intravacc has developed a strong pipeline of proprietary vaccine candidates, including those targeting infectious diseases and therapeutic applications. Their expertise is underscored by their involvement in the development of vaccines against polio, measles, and other significant diseases. Recently, Intravacc secured $633,000 in funding from CARB-X to support the development of a vaccine aimed at preventing gonorrhea infections, further demonstrating their commitment to addressing unmet health needs. With over 300 scientific publications and a robust network of global partnerships, Intravacc is well-positioned to contribute to the vaccine manufacturing industry.


19. Inventprise

  • Website: inventprise.com
  • Ownership type: Private
  • Headquarters: Redmond, Washington, United States (USA)
  • Employee distribution: United States (USA) 99%, Other 1%
  • Founded year: 2012
  • Headcount: 51-200
  • LinkedIn: inventprise-llc

Inventprise, founded in 2012 and based in Redmond, Washington, is a private biotechnology company dedicated to the development and manufacturing of vaccines. With a workforce of approximately 187 employees, Inventprise is focused on creating innovative vaccines, including their lead candidate, the Pneumococcal Conjugate Vaccine for Paediatric use. They utilize proprietary technologies, such as their Linker Conjugation Platform, to enhance vaccine efficacy and coverage. The company offers a range of services, including process development, clinical and commercial manufacturing, and quality assurance, primarily targeting healthcare providers and pharmaceutical organizations. Their state-of-the-art manufacturing facilities are designed to meet global demand, ensuring high-quality production and compliance with regulatory standards. Inventprise's commitment to advancing vaccine technology positions them as a significant contributor to public health initiatives.


20. Bilthoven Biologicals

  • Website: bbio.nl
  • Ownership type: Corporate
  • Headquarters: Bilthoven, Utrecht, Netherlands
  • Employee distribution: Netherlands 100%
  • Latest funding: $88.0M, March 2018
  • Founded year: 2012
  • Headcount: 201-500
  • LinkedIn: bilthoven-biologicals

Bilthoven Biologicals, founded in 2012 and located in Bilthoven, Utrecht, Netherlands, is a corporate entity specializing in vaccine manufacturing. The company produces essential vaccines, including Inactivated Poliomyelitis Vaccine (IPV), Diphtheria-Tetanus-Pertussis (DTP) vaccine, and Bacillus Calmette-Guérin (BCG) vaccine. Bilthoven Biologicals collaborates with prominent global health organizations, such as the World Health Organization (WHO) and UNICEF, to enhance public health and combat infectious diseases. Their operations are characterized by a strong emphasis on quality and reliability, ensuring that their vaccines meet international health standards. The company has also received significant funding, amounting to €88 million in 2018, which supports its ongoing efforts in vaccine development and production.


21. Vaxxas

  • Website: vaxxas.com
  • Ownership type: Venture Capital
  • Headquarters: Brisbane, Queensland, Australia
  • Employee distribution: Australia 95%, United States (USA) 5%
  • Latest funding: Other (Grant), $2.0M, January 2025
  • Founded year: 2011
  • Headcount: 51-200
  • LinkedIn: vaxxas

Vaxxas is a biotechnology company based in Brisbane, Queensland, Australia, founded in 2011. The company focuses on enhancing the performance of existing and next-generation vaccines through its proprietary high-density microarray patch (HD-MAP) technology. This innovative delivery system allows for needle-free vaccination, which can improve vaccine accessibility and effectiveness. Vaxxas is currently involved in various clinical trials for vaccines targeting influenza, COVID-19, and typhoid fever, aiming to address significant public health challenges. The company has received funding, including a recent grant of $3.67 million from the Wellcome Foundation to support a clinical study for a typhoid vaccine. Vaxxas is committed to advancing its HD-MAP technology, which has shown potential for self-administration and reduced cold-chain requirements, making it a promising solution for vaccine distribution, especially in lower-income regions.


22. Center of Molecular Immunology


The Center for Molecular Immunology (CIM), founded in 1994 and based in Havana, Cuba, is a private biotechnology company dedicated to the research, development, and production of therapeutic vaccines and biological products. With a workforce of over 500 employees, CIM focuses on innovative treatments for cancer and immune system diseases, particularly advanced lung cancer. Their flagship products, CIMAvax EGF and VAXIRA, have received sanitary registration for use in patients with stage III and IV advanced non-small cell lung cancer after initial chemotherapy. CIM operates under stringent Good Production Practices to ensure the quality and safety of their offerings. The company is committed to advancing therapeutic options for patients, reflecting a strong dedication to improving health outcomes in the field of oncology.


23. Arabio - Arab Company for Pharmaceutical Products


Arabio - Arab Company for Pharmaceutical Products, founded in 2005 and based in Riyadh, Saudi Arabia, is a private pharmaceutical manufacturer with a strong focus on vaccines and biological products. The company operates primarily in the MENA region, providing essential vaccines to healthcare providers and government health departments. Arabio is dedicated to improving public health by addressing vaccine-preventable diseases through its extensive product line, which includes vaccines for various diseases such as hepatitis B, meningitis, and influenza. The company has established partnerships with several global pharmaceutical firms, allowing it to manufacture and promote vaccines effectively in the region. Arabio's facility in Makkah is the first biopharmaceutical plant in the GCC, equipped with advanced manufacturing capabilities. This strategic positioning enables Arabio to play a crucial role in the local and regional vaccine supply chain, ensuring the availability of critical immunizations.


24. Mynvax Private Limited

  • Website: mynvax.com
  • Ownership type: Venture Capital
  • Headquarters: Bengaluru, Karnataka, India
  • Employee distribution: India 100%
  • Latest funding: Series A, $2.6M, May 2024
  • Founded year: 2017
  • Headcount: 11-50
  • LinkedIn: mynvax-private-limited

Mynvax Private Limited, based in Bengaluru, Karnataka, India, is a biotechnology company established in 2017. The firm specializes in the development of novel vaccines aimed at combating respiratory viral infections, notably COVID-19 and influenza. Mynvax is recognized for its innovative approach, particularly in creating recombinant, thermostable vaccines that are designed to be effective and accessible, especially for low and lower-middle-income countries. The company has made significant strides in vaccine design, having quickly developed a thermotolerant COVID-19 vaccine formulation that is effective against various viral variants. Mynvax has also initiated commercial development partnerships with vaccine manufacturers, enhancing its position in the industry. The company has received financial backing from various sources, including the incubation center of the Indian Institute of Science and BIRAC, indicating a solid foundation for its research and development efforts.



Vaccine Manufacturing Insights: Key Companies


CompanyHeadquarterSizeFoundedOwnership
Serum Institute of India Pvt. Ltd.Pune, Maharashtra, India1001-50001966Private
Bharat BiotechHyderabad, Telangana, India1001-50001996Venture Capital
Biological E. LimitedHyderabad, Telangana, India1001-50001953Venture Capital
BiovacCape Town, Western Cape, South Africa201-5002003Corporate
Indian Immunologicals LimitedHyderabad, Telangana, India1001-50001982Private
SINERGIUM BiotechGarin, Buenos Aires, Argentina201-5002011Private
AJ VaccinesFrederiksberg, Frederiksberg, Denmark501-10002017Private
VabiotechTrung Hoà, Hanoi, Vietnam1-102000Private
WalvaxKunming, Yunnan, China1001-50002001Private
FORT Biopharmaceutical companyMoscow, Moscow, Russia201-5002006Private
HipraAmer, Catalonia, Spain1001-50001954Private
ZendalTorneiros, Ourense, Spain501-10001993Private
CZ VaccinesSabaceda, Pontevedra, Spain201-5001993Corporate
MSD Sharp & Dohme GmbHAmt Neuhaus, Lower Saxony, Germany1001-50002001Private
NPO Petrovax Pharm LLCMoscow, Moscow, Russia501-10001996Venture Capital
Petrovax PharmMoscow, Moscow, Russia501-10001996Private Equity
GSK CanadaMississauga, Ontario, Canada1001-50001906Private
IntravaccBilthoven, Utrecht, Netherlands51-2002013Private
InventpriseRedmond, Washington, United States (USA)51-2002012Private
Bilthoven BiologicalsBilthoven, Utrecht, Netherlands201-5002012Corporate
VaxxasBrisbane, Queensland, Australia51-2002011Venture Capital
Center of Molecular ImmunologyHavana, Havana, Cuba1001-50001994Private
Arabio - Arab Company for Pharmaceutical ProductsRiyadh, Riyadh, Saudi Arabia51-2002005Private
Mynvax Private LimitedBengaluru, Karnataka, India11-502017Venture Capital


Want to Find More Vaccine Manufacturing Companies?

If you want to find more companies that provide vaccines and biopharmaceutical products you can do so with Inven. This list was built with Inven and there are hundreds of companies like these globally.

With Inven you'll also get to know the company's:

  • Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
  • Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
  • Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!